Your browser is no longer supported. Please, upgrade your browser.
Settings
FGEN FibroGen, Inc. daily Stock Chart
FGEN [NASD]
FibroGen, Inc.
Index- P/E- EPS (ttm)-1.04 Insider Own3.70% Shs Outstand108.12M Perf Week-1.70%
Market Cap3.87B Forward P/E167.93 EPS next Y0.21 Insider Trans-12.17% Shs Float76.82M Perf Month-22.48%
Income-86.40M PEG- EPS next Q-0.39 Inst Own67.10% Short Float4.50% Perf Quarter-38.85%
Sales213.00M P/S18.16 EPS this Y-14.30% Inst Trans0.79% Short Ratio4.12 Perf Half Y-12.05%
Book/sh5.98 P/B5.98 EPS next Y122.90% ROA-16.30% Target Price70.43 Perf Year-32.00%
Cash/sh5.75 P/C6.22 EPS next 5Y- ROE-28.60% 52W Range33.51 - 68.55 Perf YTD-22.71%
Dividend- P/FCF- EPS past 5Y-30.80% ROI-14.00% 52W High-47.82% Beta1.59
Dividend %- Quick Ratio7.80 Sales past 5Y15.80% Gross Margin- 52W Low6.74% ATR2.65
Employees461 Current Ratio7.80 Sales Q/Q252.10% Oper. Margin-66.80% RSI (14)28.00 Volatility6.10% 4.95%
OptionableYes Debt/Eq0.22 EPS Q/Q-5.00% Profit Margin-66.30% Rel Volume1.37 Prev Close37.32
ShortableYes LT Debt/Eq0.22 EarningsMay 09 AMC Payout- Avg Volume838.30K Price35.77
Recom1.60 SMA20-19.91% SMA50-28.52% SMA200-30.53% Volume1,149,341 Change-4.15%
May-10-19Downgrade William Blair Outperform → Mkt Perform
Apr-12-19Initiated Piper Jaffray Neutral $65
Feb-11-19Resumed Stifel Buy $71
Dec-19-18Upgrade Citigroup Neutral → Buy
Aug-08-17Reiterated Stifel Buy $38 → $80
Aug-08-17Reiterated Leerink Partners Outperform $52 → $82
Jul-21-17Downgrade Goldman Buy → Neutral
Jul-11-17Initiated Jefferies Buy
Feb-11-16Upgrade Credit Suisse Neutral → Outperform $40
Jan-21-16Initiated Credit Suisse Neutral
Dec-04-15Initiated Citigroup Buy
Sep-23-15Initiated Lake Street Hold $25
Jul-29-15Initiated Citigroup Buy $37
Jul-20-15Upgrade Goldman Neutral → Buy
Dec-09-14Initiated Stifel Buy $39
Dec-09-14Initiated RBC Capital Mkts Outperform $38
May-16-19 08:54AM  Implied Volatility Surging for FibroGen (FGEN) Stock Options Zacks
May-15-19 01:00PM  FibroGen INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In FibroGen, Inc. To Contact The Firm ACCESSWIRE
May-14-19 09:07PM  Edited Transcript of FGEN earnings conference call or presentation 9-May-19 9:00pm GMT Thomson Reuters StreetEvents +6.60%
May-13-19 06:26AM  FibroGen Inc (FGEN) Q1 2019 Earnings Call Transcript Motley Fool
May-10-19 08:36PM  FibroGen INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In FibroGen, Inc. To Contact The Firm GlobeNewswire -20.32%
02:29PM  Here's Why FibroGen Fell as Much as 26.6% Today Motley Fool
12:50PM  FibroGen News: Why FGEN Stock Is Plummeting Today InvestorPlace
08:00AM  The Daily Biotech Pulse: FibroGen Kidney Disease Trial Disappoints, Medtronic To Buy Titan Spine, Puma's Weak Breast Cancer Drug Sales Benzinga
May-09-19 08:25PM  FibroGen (FGEN) Reports Q1 Loss, Tops Revenue Estimates Zacks
07:19PM  FibroGen: 1Q Earnings Snapshot Associated Press
04:44PM  FibroGen Reports First Quarter 2019 Financial Results GlobeNewswire
04:43PM  FibroGen Announces Positive Topline Results from Pooled Safety Analyses of Roxadustat Global Phase 3 Program GlobeNewswire
May-06-19 05:00PM  FibroGen to Report First Quarter 2019 Financial Results GlobeNewswire
May-02-19 02:34PM  Zoetis (ZTS) Earnings Beat Estimates in Q1, Revenues Miss Zacks
May-01-19 10:33AM  Analysts Estimate FibroGen (FGEN) to Report a Decline in Earnings: What to Look Out for Zacks
07:39AM  How Does Investing In FibroGen, Inc. (NASDAQ:FGEN) Impact The Volatility Of Your Portfolio? Simply Wall St.
Apr-26-19 09:18AM  Heres What Hedge Funds Think About FibroGen Inc (FGEN) Insider Monkey
Apr-22-19 12:28AM  Health Care Digest: Attacking a deadly infant virus, Medicaid's smoking gun and exporting genetic expertise American City Business Journals
Apr-15-19 07:00AM  FibroGen Receives Orphan Drug Designation from the U.S. FDA For Pamrevlumab for the Treatment of Duchenne Muscular Dystrophy GlobeNewswire
Apr-10-19 10:30AM  Akebia Expands Vadadustat Licensing Deal With Vifor Pharma Zacks
Apr-08-19 03:38PM  Is FibroGen, Inc. (NASDAQ:FGEN) A Financially Strong Company? Simply Wall St.
Apr-03-19 10:48AM  Options Traders Expect Huge Moves in FibroGen (FGEN) Stock Zacks
Apr-02-19 07:07AM  4 Biotech Stocks With Major Catalysts in April Motley Fool
Mar-07-19 02:16PM  FibroGen, Inc. (NASDAQ:FGEN): Commentary On Fundamentals Simply Wall St.
Mar-06-19 05:50PM  More biotech takeover targets coming, says Jefferies top analyst CNBC Videos
Mar-05-19 04:06PM  What's in the Cards for Corbus (CRBP) This Earnings Season? Zacks
Mar-04-19 12:40PM  Edited Transcript of FGEN earnings conference call or presentation 27-Feb-19 10:00pm GMT Thomson Reuters StreetEvents
Feb-28-19 12:45AM  FibroGen Inc (FGEN) Q4 2018 Earnings Conference Call Transcript Motley Fool
Feb-27-19 04:08PM  FibroGen Reports Fourth Quarter and Full Year 2018 Financial Results GlobeNewswire
Feb-22-19 11:43PM  FibroGen Reports Fourth Quarter and Full Year 2018 Financial Results GlobeNewswire
04:36PM  What's in Store for Teladoc's (TDOC) Q4 Earnings? Zacks
Feb-20-19 09:32AM  Tenet Healthcare (THC) Q4 Earnings: What's in the Offing? Zacks
Feb-06-19 10:50AM  How Much is FibroGen, Inc.s (NASDAQ:FGEN) CEO Getting Paid? Simply Wall St.
Jan-17-19 08:00AM  Today's Research Reports on Trending Tickers: Ligand Pharmaceuticals and FibroGen ACCESSWIRE
07:35AM  Analysis: Positioning to Benefit within Motorola Solutions, FibroGen, UnitedHealth Group, Newell Brands, Vuzix, and Choice Hotels International Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Dec-20-18 04:14PM  Can This Biotech Stock Rival Amgen In Anemia? Analyst Says Yes Investor's Business Daily
02:24PM  [$$] Big Pharma Wins Drug Approval in China Ahead of West for First Time The Wall Street Journal
09:09AM  AstraZeneca stock up 2.8% after announcing EU approval of COPD treatment MarketWatch
07:00AM  Today's Research Reports on Trending Tickers: Aimmune Therapeutics and FibroGen ACCESSWIRE
07:00AM  FibroGen Announces Positive Topline Results from Three Global Phase 3 Trials of Roxadustat for Treatment of Anemia in Patients with Chronic Kidney Disease GlobeNewswire
Dec-19-18 01:21AM  FibroGen Inc (FGEN): Hedge Fund Sentiment Unchanged Insider Monkey
Dec-18-18 08:21PM  [$$] Big Pharma Wins Drug Approval in China Ahead of West for First Time The Wall Street Journal
05:18PM  Why a kidney disease drug approval in China is just the start for this S.F. company American City Business Journals
08:00AM  The Daily Biotech Pulse: Puma Aces Late-Stage Trial, Chinese Cheer For FibroGen, J&J $5B Buyback Plan Benzinga
07:00AM  Today's Research Reports on Trending Tickers: Puma Biotechnology and FibroGen ACCESSWIRE
06:24AM  China first to approve AstraZeneca, FibroGen anaemia drug Reuters
Dec-17-18 06:07PM  FibroGen Announces Approval of Roxadustat in China for the Treatment of Anemia in Chronic Kidney Disease Patients on Dialysis GlobeNewswire
12:21PM  How Many Insiders Sold FibroGen, Inc. (NASDAQ:FGEN) Shares? Simply Wall St.
Dec-06-18 04:00AM  FibroGen Appoints Maykin Ho, Ph.D., to Board of Directors GlobeNewswire
Nov-27-18 08:45AM  New Research Coverage Highlights Phibro Animal Health, RadNet, Amphastar Pharmaceuticals, FibroGen, Sientra, and Flexion Therapeutics Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Nov-16-18 11:47AM  Edited Transcript of FGEN earnings conference call or presentation 8-Nov-18 10:00pm GMT Thomson Reuters StreetEvents
Nov-14-18 06:55AM  Today's Research Reports on Trending Tickers: Amicus Therapeutics and FibroGen ACCESSWIRE
Nov-08-18 06:40PM  FibroGen (FGEN) Reports Q3 Loss, Lags Revenue Estimates Zacks
05:35PM  FibroGen: 3Q Earnings Snapshot Associated Press
04:02PM  FibroGen Reports Third Quarter 2018 Financial Results GlobeNewswire
Nov-05-18 01:55PM  What Kind Of Shareholder Appears On The FibroGen Incs (NASDAQ:FGEN) Shareholder Register? Simply Wall St. -5.91%
Nov-02-18 05:02PM  FibroGen to Report Third Quarter 2018 Financial Results on Thursday, November 8, 2018 GlobeNewswire
Oct-30-18 04:00AM  ASN Kidney Week 2018: Data Presented from Two Japanese Phase 3 Studies on Roxadustat in the Treatment of Anemia Associated with Chronic Kidney Disease in Patients on Dialysis GlobeNewswire
Oct-25-18 07:49PM  FibroGen Presents Results from Two Phase 3 Studies of Roxadustat for the Treatment of Anemia Associated with Chronic Kidney Disease Conducted in China at American Society of Nephrology Kidney Week 2018 Annual Meeting GlobeNewswire
Oct-18-18 08:00AM  Today's Research Reports on Trending Tickers: Immunomedics and FibroGen ACCESSWIRE
Oct-16-18 04:27PM  FibroGen Announces Four Clinical Presentations on Roxadustat at Upcoming American Society of Nephrology Kidney Week 2018 Annual Meeting GlobeNewswire +7.75%
08:30AM  Research Report Identifies The Habit Restaurants, Datawatch, SMART SAND INC, Independence Contract Drilling, Pareteum, and FibroGen with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Oct-01-18 08:00AM  Astellas Submits New Drug Application in Japan of Roxadustat for The Treatment of Anemia Associated with Chronic Kidney Disease in Patients on Dialysis GlobeNewswire
Sep-28-18 03:09PM  All You Need To Know About FibroGen Incs (NASDAQ:FGEN) Financial Health Simply Wall St.
Sep-25-18 08:00AM  Today's Research Reports on Trending Tickers: Ultragenyx Pharmaceutical and FibroGen ACCESSWIRE
Sep-24-18 11:10AM  Health Care Digest: Genentech's neuro legacy, uBiome's haul, plus saving moms American City Business Journals
Sep-19-18 03:02AM  Focus: AstraZeneca plots China robot offensive to counter price cuts Reuters
02:03AM  AstraZeneca plots China robot offensive to counter price cuts Reuters
01:08AM  AstraZeneca plots China robot offensive to counter price cuts Reuters
Sep-12-18 09:30AM  FibroGen Receives Fast Track Designation From the U.S. FDA for Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis GlobeNewswire
Sep-05-18 05:19AM  Boost for "made in China" medicine as Chi-Med wins key approval Reuters
Aug-15-18 07:55AM  New Research: Key Drivers of Growth for comScore, Fonar, FibroGen, Resolute Energy, National Commerce, and THL Credit Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Aug-07-18 07:20PM  FibroGen (FGEN) Reports Q2 Loss, Tops Revenue Estimates Zacks
06:13PM  FibroGen: 2Q Earnings Snapshot Associated Press
04:02PM  FibroGen Reports Second Quarter 2018 Financial Results GlobeNewswire
Aug-01-18 05:21PM  FibroGen to Report Second Quarter 2018 Financial Results on Tuesday, August 7, 2018 GlobeNewswire
Jul-10-18 07:45AM  Free Pre-Market Technical Pulse on FibroGen and Three More Biotech Stocks ACCESSWIRE
Jun-11-18 07:00AM  Blog Exposure - FibroGen Completed Enrollment in US Phase-3 Clinical Program for Roxadustat in CKD Associated Anemia ACCESSWIRE
Jun-07-18 07:00AM  FibroGen Announces Completion of Enrollment in U.S. Phase 3 Clinical Program for Roxadustat in Anemia Associated with Chronic Kidney Disease GlobeNewswire
Jun-04-18 02:05PM  FibroGen to Present at Two Upcoming Investor Conferences GlobeNewswire
Jun-03-18 09:30PM  FibroGen Presents Clinical Results of Pamrevlumab Treatment in Patients with Locally Advanced Unresectable Pancreatic Cancer at ASCO 2018 Annual Meeting GlobeNewswire
Jun-01-18 09:30AM  FibroGen Inc (NASDAQ:FGEN) Investors Are Paying Above The Intrinsic Value Simply Wall St.
May-21-18 04:00PM  FibroGen Presents Latest Data From PRAISE Phase 2b Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis at American Thoracic Society 2018 GlobeNewswire
May-15-18 05:29PM  FibroGen Upgraded By Mizuho On Continued R&D Progress Benzinga
May-10-18 06:06PM  Edited Transcript of FGEN earnings conference call or presentation 9-May-18 9:00pm GMT Thomson Reuters StreetEvents -5.61%
May-09-18 05:31PM  FibroGen: 1Q Earnings Snapshot Associated Press
04:02PM  FibroGen Reports First Quarter 2018 Financial Results GlobeNewswire
May-02-18 07:00AM  FibroGen to Report First Quarter 2018 Financial Results on Wednesday, May 9, 2018 GlobeNewswire
Apr-27-18 07:45AM  Consolidated Research: 2018 Summary Expectations for MGM Growth Properties, Reinsurance Group of America, Cincinnati Bell, GAIN Capital, FibroGen, and First Hawaiian Fundamental Analysis, Key Performance Indications GlobeNewswire
Mar-05-18 07:40AM  Wired News FDA Granted Fast Track Designation to FibroGens Pamrevlumab for Locally Advanced Unresectable Pancreatic Cancer ACCESSWIRE
Mar-02-18 06:11PM  Edited Transcript of FGEN earnings conference call or presentation 27-Feb-18 10:00pm GMT Thomson Reuters StreetEvents
Mar-01-18 01:45PM  UPDATE - FibroGen Granted Fast Track Designation by U.S. FDA for Pamrevlumab Treatment of Patients with Locally Advanced Unresectable Pancreatic Cancer GlobeNewswire
07:55AM  Report: Developing Opportunities within Main Street Capital, United States Cellular, FibroGen, Cardiovascular, CDW, and ANSYS Future Expectations, Projections Moving into 2018 GlobeNewswire
07:00AM  Fibrogen Granted Fast Track Designation by U.S. FDA for Pamrevlumab Treatment of Patients with Locally Advanced Unresectable Pancreatic Cancer GlobeNewswire
Feb-28-18 05:04AM  FibroGen reports 4Q loss Associated Press -5.73%
Feb-27-18 04:11PM  FibroGen Reports Fourth Quarter and Full Year 2017 Financial Results GlobeNewswire
01:30PM  FibroGen, Inc. to Host Earnings Call ACCESSWIRE
12:53PM  FibroGen Q4 Earnings Outlook Benzinga
07:27AM  FibroGen Incs (NASDAQ:FGEN) Earnings Dropped -74.69%, Did Its Industry Show Weakness Too? Simply Wall St.
Feb-21-18 07:00AM  FibroGen to Report Fourth Quarter and Full Year 2017 Financial Results on Tuesday, February 27, 2018 GlobeNewswire
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. The company is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Duchenne muscular dystrophy; and FG-5200, a corneal implant medical device for the treatment of corneal blindness resulting from partial thickness corneal damage. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was incorporated in 1993 and is headquartered in San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Rosenkranz Roberto PedroDirectorMay 15Option Exercise16.4930,000494,73062,700May 17 04:49 PM
Neff Thomas BChief Executive OfficerMay 14Option Exercise2.906,83419,8192,515,478May 15 07:50 PM
Neff Thomas BChief Executive OfficerMay 14Sale36.8718,400678,4362,497,078May 15 07:50 PM
Neff Thomas BChief Executive OfficerMay 14Sale36.901,41852,33164,090May 15 07:50 PM
Neff Thomas BChief Executive OfficerMay 13Option Exercise2.906,83419,8192,527,044May 15 07:50 PM
Neff Thomas BChief Executive OfficerMay 13Sale35.8218,400659,0752,508,644May 15 07:50 PM
Neff Thomas BChief Executive OfficerMay 13Sale35.761,41850,71265,508May 15 07:50 PM
Kurkijarvi KaleviDirectorMay 08Option Exercise2.906,00017,40029,700May 10 06:07 PM
Chung ChristineSVP, China OperationsMay 08Option Exercise29.665,625166,838163,562May 09 09:08 PM
Kurkijarvi KaleviDirectorMay 08Sale45.946,000275,62223,700May 10 06:07 PM
Chung ChristineSVP, China OperationsMay 08Sale46.315,625260,505157,937May 09 09:08 PM
Schoeneck James ADirectorMay 07Option Exercise2.902,0005,8005,700May 09 09:00 PM
Chung ChristineSVP, China OperationsMay 07Option Exercise29.665,625166,838163,562May 09 09:08 PM
Schoeneck James ADirectorMay 07Sale47.022,00094,0453,700May 09 09:00 PM
Chung ChristineSVP, China OperationsMay 07Sale46.505,625261,565157,937May 09 09:08 PM
Cotroneo PatSVP, Finance and CFOMay 06Option Exercise2.907,00020,300256,504May 08 06:45 PM
Neff Thomas BChief Executive OfficerApr 18Option Exercise2.906,83419,8192,538,610Apr 19 05:07 PM
Neff Thomas BChief Executive OfficerApr 18Sale46.8118,400861,2632,520,210Apr 19 05:07 PM
Neff Thomas BChief Executive OfficerApr 18Sale46.881,41866,47066,926Apr 19 05:07 PM
Neff Thomas BChief Executive OfficerApr 17Option Exercise2.906,83419,8192,550,176Apr 19 05:07 PM
Neff Thomas BChief Executive OfficerApr 17Sale46.7218,400859,6292,531,776Apr 19 05:07 PM
Neff Thomas BChief Executive OfficerApr 17Sale46.631,41866,12868,344Apr 19 05:07 PM
Cotroneo PatSVP, Finance and CFOApr 15Option Exercise2.9010,00029,000249,504Apr 17 08:18 PM
Kurkijarvi KaleviDirectorApr 15Option Exercise2.904,00011,60027,700Apr 17 08:19 PM
Kurkijarvi KaleviDirectorApr 15Sale48.094,000192,36023,700Apr 17 08:19 PM
Kurkijarvi KaleviDirectorApr 08Option Exercise2.904,00011,60027,700Apr 10 07:41 PM
Schoeneck James ADirectorApr 08Option Exercise2.902,0005,80029,700Apr 10 07:43 PM
Kurkijarvi KaleviDirectorApr 08Sale53.034,000212,12123,700Apr 10 07:41 PM
Schoeneck James ADirectorApr 08Sale52.902,000105,80027,700Apr 10 07:43 PM
Neff Thomas BChief Executive OfficerApr 04Option Exercise2.906,83419,8192,561,742Apr 05 06:54 PM
Neff Thomas BChief Executive OfficerApr 04Sale53.381,41875,69569,762Apr 05 06:54 PM
Neff Thomas BChief Executive OfficerApr 04Sale53.5218,400984,7632,543,342Apr 05 06:54 PM
Neff Thomas BChief Executive OfficerApr 03Option Exercise2.906,83419,8192,573,308Apr 05 06:54 PM
Neff Thomas BChief Executive OfficerApr 03Sale54.601,41877,42371,180Apr 05 06:54 PM
Neff Thomas BChief Executive OfficerApr 03Sale54.6418,4001,005,3142,554,908Apr 05 06:54 PM
Routti JormaDirectorMar 26Option Exercise22.7530,000682,440161,540Mar 27 06:27 PM
Neff Thomas BChief Executive OfficerMar 21Option Exercise2.906,83419,8192,584,874Mar 22 05:37 PM
Neff Thomas BChief Executive OfficerMar 21Sale55.831,41879,16772,598Mar 22 05:37 PM
Neff Thomas BChief Executive OfficerMar 21Sale55.6018,4001,023,0122,566,474Mar 22 05:37 PM
Neff Thomas BChief Executive OfficerMar 20Option Exercise2.906,83419,8192,596,440Mar 22 05:37 PM
Neff Thomas BChief Executive OfficerMar 20Sale55.611,41878,85074,016Mar 22 05:37 PM
Neff Thomas BChief Executive OfficerMar 20Sale55.4118,4001,019,5902,578,040Mar 22 05:37 PM
Cotroneo PatSVP, Finance and CFOMar 19Sale55.417,665424,718239,504Mar 20 06:47 PM
Yu K PeonyChief Medical OfficerMar 14Sale56.309,145514,864182,440Mar 15 06:11 PM
Neff Thomas BChief Executive OfficerMar 07Option Exercise2.906,83419,8192,608,006Mar 08 06:41 PM
Schoeneck James ADirectorMar 07Option Exercise2.902,0005,80029,700Mar 08 06:47 PM
Neff Thomas BChief Executive OfficerMar 07Sale54.9418,4001,010,8442,589,606Mar 08 06:41 PM
Neff Thomas BChief Executive OfficerMar 07Sale54.931,41877,89075,434Mar 08 06:41 PM
Schoeneck James ADirectorMar 07Sale54.742,000109,47227,700Mar 08 06:47 PM
Neff Thomas BChief Executive OfficerMar 06Option Exercise2.906,83419,8192,619,572Mar 08 06:41 PM
Neff Thomas BChief Executive OfficerMar 06Sale56.3818,4001,037,3162,601,172Mar 08 06:41 PM
Neff Thomas BChief Executive OfficerMar 06Sale56.251,41879,76976,852Mar 08 06:41 PM
Cotroneo PatSVP, Finance and CFOFeb 28Option Exercise29.6614,787438,582267,891Mar 01 06:05 PM
Cotroneo PatSVP, Finance and CFOFeb 28Sale60.0814,787888,391253,104Mar 01 06:05 PM
Neff Thomas BChief Executive OfficerFeb 20Option Exercise3.6010,31937,1482,649,475Feb 21 07:47 PM
Neff Thomas BChief Executive OfficerFeb 20Sale57.0691852,37778,270Feb 21 07:47 PM
Neff Thomas BChief Executive OfficerFeb 20Sale57.1118,9001,079,3052,630,575Feb 21 07:47 PM
Neff Thomas BChief Executive OfficerFeb 19Option Exercise3.6010,31937,1482,658,056Feb 21 07:47 PM
Neff Thomas BChief Executive OfficerFeb 19Sale57.6791852,94179,188Feb 21 07:47 PM
Neff Thomas BChief Executive OfficerFeb 19Sale57.7118,9001,090,7972,639,156Feb 21 07:47 PM
Neff Thomas BChief Executive OfficerFeb 08Option Exercise3.6010,31937,1482,666,637Feb 08 06:58 PM
Neff Thomas BChief Executive OfficerFeb 08Sale56.8991852,22280,106Feb 08 06:58 PM
Neff Thomas BChief Executive OfficerFeb 08Sale56.9118,9001,075,5952,647,737Feb 08 06:58 PM
Neff Thomas BChief Executive OfficerFeb 07Option Exercise3.6010,31937,1482,680,346Feb 08 06:58 PM
Schoeneck James ADirectorFeb 07Option Exercise2.902,0005,80029,700Feb 08 07:00 PM
Neff Thomas BChief Executive OfficerFeb 07Sale56.1628,3621,592,86081,024Feb 08 06:58 PM
Schoeneck James ADirectorFeb 07Sale57.172,000114,34027,700Feb 08 07:00 PM
Neff Thomas BChief Executive OfficerJan 23Option Exercise3.6010,31937,1482,604,335Jan 24 07:32 PM
Neff Thomas BChief Executive OfficerJan 23Sale51.9927,9081,451,0182,576,427Jan 24 07:32 PM
Neff Thomas BChief Executive OfficerJan 23Sale52.332,092109,48585,358Jan 24 07:32 PM
Neff Thomas BChief Executive OfficerJan 22Option Exercise3.6010,31937,1482,624,016Jan 24 07:32 PM
Neff Thomas BChief Executive OfficerJan 22Sale51.9930,0001,559,6402,594,016Jan 24 07:32 PM
Schoeneck James ADirectorJan 07Option Exercise2.902,0005,80029,700Jan 09 06:48 PM
Schoeneck James ADirectorJan 07Sale45.902,00091,80027,700Jan 09 06:48 PM
Neff Thomas BChief Executive OfficerJan 04Option Exercise3.6020,91275,2832,643,697Jan 07 07:20 PM
Neff Thomas BChief Executive OfficerJan 04Sale44.9130,0001,347,4082,613,697Jan 07 07:20 PM
Neff Thomas BChief Executive OfficerJan 03Option Exercise3.6030,000108,0002,652,785Jan 07 07:20 PM
Neff Thomas BChief Executive OfficerJan 03Sale43.8730,0001,316,0722,622,785Jan 07 07:20 PM
Rosenkranz Roberto PedroDirectorDec 20Option Exercise9.781,0009,77533,700Dec 21 04:22 PM
Rosenkranz Roberto PedroDirectorDec 20Sale41.001,00041,00032,700Dec 21 04:22 PM
Kurkijarvi KaleviDirectorDec 19Option Exercise2.904,00011,60027,700Dec 21 04:20 PM
Kurkijarvi KaleviDirectorDec 19Sale41.324,000165,28823,700Dec 21 04:20 PM
Cotroneo PatSVP, Finance and CFODec 18Sale41.103,330136,863222,004Dec 20 08:34 PM
Yu K PeonyChief Medical OfficerDec 14Sale38.583,422132,021144,123Dec 18 08:05 PM
Neff Thomas BChief Executive OfficerDec 06Option Exercise3.6011,00239,6072,650,949Dec 06 08:45 PM
Neff Thomas BChief Executive OfficerDec 06Sale40.9328,1641,152,6662,622,785Dec 06 08:45 PM
Neff Thomas BChief Executive OfficerDec 06Sale40.911,83675,11187,450Dec 06 08:45 PM
Neff Thomas BChief Executive OfficerNov 21Option Exercise3.6010,31937,1482,667,507Nov 21 06:23 PM
Neff Thomas BChief Executive OfficerNov 21Sale39.4718,900745,9832,648,607Nov 21 06:23 PM
Neff Thomas BChief Executive OfficerNov 21Sale39.4791836,23389,286Nov 21 06:23 PM
Neff Thomas BChief Executive OfficerNov 20Option Exercise3.6010,31937,1482,676,088Nov 21 06:23 PM
Neff Thomas BChief Executive OfficerNov 20Sale39.2618,900742,0412,657,188Nov 21 06:23 PM
Neff Thomas BChief Executive OfficerNov 20Sale39.2591836,03190,204Nov 21 06:23 PM
Kurkijarvi KaleviDirectorNov 15Option Exercise2.904,00011,60027,700Nov 16 06:24 PM
Rosenkranz Roberto PedroDirectorNov 15Option Exercise9.781,0009,77533,700Nov 16 06:28 PM
Rosenkranz Roberto PedroDirectorNov 15Sale39.241,00039,24032,700Nov 16 06:28 PM
Kurkijarvi KaleviDirectorNov 15Sale39.774,000159,09423,700Nov 16 06:24 PM
Neff Thomas BChief Executive OfficerNov 02Option Exercise3.6010,31937,1482,684,669Nov 02 06:40 PM
Neff Thomas BChief Executive OfficerNov 02Sale44.6191840,95291,122Nov 02 06:40 PM
Neff Thomas BChief Executive OfficerNov 02Sale44.6018,900842,8662,665,769Nov 02 06:40 PM